Our pipeline demonstrates our ability to rapidly translate scientific concepts and patient-centric data into precision-designed therapeutic candidates.

<div class="pipelinePageIntro"><h1>Pipeline</h1><p>Our pipeline demonstrates the ability of our AI-driven drug discovery platform to create precision engineered, patient-centric therapeutic candidates. </p></div>

<p><span style="font-size: 24px;">*</span> Phase 3 may not be required if Phase 2 is registrational: PKC-theta is in a Phase 1 healthy volunteer study. Does not include Sumitomo Pharma programmes.</p>

Pipeline

Programme

Target

Late Discovery

IND-enabling

Phase 1/2

Phase 3 / Approved*

Exscientia Rights